Methods of treating CD166-expressing cancer
AssigneeThe Trustees of Columbia University in the City of New York
InventorsNicole Suciu-Foca, George Vlad, Zheng Xu
Life of this patent
Estimating the term…
Abstract
It has now been discovered that activated lymphocyte cell adhesion molecule (ALCAM)—also known as CD166—is the ligand of the innate immune receptor ILT3 that is expressed by DC and monocytes. It has been further discovered that the specific binding of ILT3 to its ligand CD166 on the surface of CD166-expressing cancer cells, arrested cancer cell growth and initiated apoptosis. Therefore, certain embodiments relate to methods and compositions for treating CD166-expressing cancers by administering ILT3Fc, full-length ILT3 or any CD166 ligand-binding fragment thereof.
Claims5
A method comprising administering to a subject having a CD166-expressing cancer a therapeutically effective amount of an agent selected from the group consisting of full length ILT3, the extracellular domain of ILT3 and LT3Fc thereby treating the cancer, wherein the agent inhibits the interaction between ILT3 expressed on monocytes, macrophages, and dendritic cells with CD166 expressed on cancer cells, and the therapeutically effective amount significantly reduces the proliferation of the CD166-expressing cancer cells compared to respective pretreatment levels or significantly increases apoptosis of the CD166-expressing cancer cells compared to a pretreatment level.
Dependencies are inferred from the claim text.